Table 3 Characteristics of uncontrolled NVAF patients (treated with VKAs)
Uncontrolled patients | Patients with data (N) | |
|---|---|---|
BMI (kg/m2, mean ± SD) | 28.7 (5.4) | 142 |
Creatine clearance (ml/min, mean ± SD) | 57.2 (26.6) | 150 |
> 80 years | 50.9 (21.5) | |
75–80 years | 56.4 (14.4) | |
65–74 years | 73.5 (36.5) | |
18–64 years | 74.3 (37.6) | |
Quantitative LVEF (%, mean ± SD) | 56.1 (11.2) | 108 |
Qualitative LVEF [n (%)] | 161 | |
Normal (≥ 50%) | 140 (87) | |
Slightly depressed (49–41%) | 5 (3.1) | |
Moderately depressed (40–31%) | 10 (6.2) | |
Severely depressed (≤ 30%) | 6 (3.7) | |
CHA2DS2-VASc score (mean ± SD) | 4.5 (1.4)a | 171 |
> 80 years | 4.8 (1.2) | |
75–80 years | 4.7 (1.4) | |
65–74 years | 3.7 (1.2) | |
18–64 years | 3.1 (1.2) | |
HAS-BLED score [n (%)] | 171 | |
Low-medium risk (score < 3) | 27 (15.8) | |
> 80 years | 12 (11.4) | |
75–80 years | 3 (12.5) | |
65–74 years | 5 (15.6) | |
18–64 years | 7 (70.0) | |
High risk (score ≥ 3) | 144 (84.2) | |
> 80 years | 93 (88.6) | |
75–80 years | 21 (87.5) | |
65–74 years | 27 (84.4) | |
18–64 years | 3 (30.0) | |
History of thromboembolic event [n (%)] | 60 (35.1) | 171 |
History of haemorrhagic event [n (%)] | 25 (14.6) | 171 |
Comorbidities [n (%)] | 169 (98.8) | 171 |
Hypertension | 145 (85.8) | |
Congestive heart failure | 82 (48.5) | |
Diabetes mellitus | 65 (38.5) | |
Renal failure | 58 (34.3) | |
Anaemia | 55 (32.5) | |
Arterial vascular disease | 33 (19.5) | |
Previous stroke/transient ischaemic attack | 30 (17.8) | |
Otherb | 67 (39.6) | |
Concomitant treatments [n (%)]c | 166 (97.1) | 171 |
Furosemide | 67 (39.2) | |
Bisoprolol | 46 (26.9) | |
Atorvastatin | 34 (19.9) | |
Omeprazole | 34 (19.9) | |
Enalapril | 30 (17.5) | |
Metformin | 24 (14.0) | |
Allopurinol | 20 (11.7) | |
Digoxin | 18 (10.5) | |
Number of visits to the internal medicine specialist per year (mean ± SD) | 3.1 (1.9) | 171 |